Pathan
Aijaz Pathan, Austin, TX US
Patent application number | Description | Published |
---|---|---|
20120143876 | Method and Apparatus for Efficiently Organizing Hierarchical QoS Policies - Consistent with embodiments of the present invention, a method may be provided comprising receiving a search string corresponding to a desired node comprising a target parameter, a policy parameter, and a class parameter. The target parameter may be referenced with a target index table to determine which interfaces to search. The policy parameter may be referenced with a policy index table to determine a node-id of a policy node corresponding to the policy parameter. A level for the desired node may be determined based on the node-id. The class parameter may be referenced with the determined node-id with a class index table to access a bucket location. The desired node may then be searched for with the determined node-id at the determined level. | 06-07-2012 |
Ansar Pathan, Oxford GB
Patent application number | Description | Published |
---|---|---|
20100041075 | Tuberculosis Diagnostic Test - A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided. | 02-18-2010 |
20110201044 | TUBERCULOSIS DIAGNOSTIC TEST - A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided. | 08-18-2011 |
20120264141 | TUBERCULOSIS DIAGNOSTIC TEST - A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided. | 10-18-2012 |
20130310271 | TUBERCULOSIS DIAGNOSTIC TEST - A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided. | 11-21-2013 |
Ansar A. Pathan, Oxford GB
Patent application number | Description | Published |
---|---|---|
20080226678 | Compositions for Immunizing Against Mycobacterium - A method for generating a T cell immune response in a host involving administering a vectored vaccine comprising a non-replicating or replication impaired viral vector expressing the translation product of a mycobacterial antigen 85A gene. Vectored vaccines and uses thereof are also provided. Also provided is a method of inducing a CD8 and a CD4 memory T cell response against an antigen using an adenovirus vector expressing an antigen or an immunogenic fragment thereof. | 09-18-2008 |
Arnavkumar M. Pathan, Sunnyvale, CA US
Patent application number | Description | Published |
---|---|---|
20090245199 | WIRELESS HAND-OVER IN MOBILE DEPLOYMENTS - The network communication system includes a wireless interface to exchange wireless signals during at least one network connection, and a handover controller that uses a route profile identifying access points distributed over a given route or region that are capable of supporting the network connection, and to handover the network connection between access points as the device travels along the given route or through a region according to the route profile. | 10-01-2009 |
Asif Imtiyaz Pathan, Sunnyvale, CA US
Patent application number | Description | Published |
---|---|---|
20150355985 | RECOVERY CONSUMER FRAMEWORK - A recovery consumer framework provides for execution of recovery actions by one or more recovery consumers to enable efficient recovery of information (e.g., data and metadata) in a storage system after a failure event (e.g., a power failure). The recovery consumer framework permits concurrent execution of recovery actions so as to reduce recovery time (i.e., duration) for the storage system. The recovery consumer framework may coordinate (e.g., notify) the recovery consumers to serialize execution of the recovery actions by those recovery consumers having a dependency while allowing concurrent execution between recovery consumers having no dependency relationship. Each recovery consumer may register with the framework to associate a dependency on one or more of the other recovery consumers. The dependency association may be represented as a directed graph where each vertex of the graph represents a recovery consumer and each directed edge of the graph represents a dependency. The framework may traverse (i.e., walk) the framework graph and for each vertex encountered, notify the associated recovery consumer to initiate its respective recovery actions. | 12-10-2015 |
Nuzhat Pathan, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20080213167 | USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS - Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL). | 09-04-2008 |
20080213168 | USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS - Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL). | 09-04-2008 |
20080213260 | USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS - Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL). | 09-04-2008 |
20100144730 | PYRIDINONYL PDK1 INHIBITORS - The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same. | 06-10-2010 |
20150018351 | PYRIDINONYL PDK1 INHIBITORS - The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same. | 01-15-2015 |
Shadab Ahmad Pathan, Gurgaon, Haryana IN
Patent application number | Description | Published |
---|---|---|
20160113868 | NICOTINE LOZENGE FORMULATION - Aspects of the present invention are directed to a nicotine lozenge for oral administration comprising: a nicotine active; at least one high viscosity, water soluble, synthetic or semi-synthetic, non-ionic polymer; and at least one low viscosity, water soluble, synthetic or semi-synthetic, non-ionic polymer. Lozenges of the present invention are more stable and less expensive than traditional lozenges. | 04-28-2016 |
Shukur Moulali Pathan, San Jose, CA US
Patent application number | Description | Published |
---|---|---|
20110185125 | RESOURCE SHARING TO REDUCE IMPLEMENTATION COSTS IN A MULTICORE PROCESSOR - A processor may include several processor cores, each including a respective higher-level cache; a lower-level cache including several tag units each including several controllers, where each controller corresponds to a respective cache bank configured to store data, and where the controllers are concurrently operable to access their respective cache banks; and an interconnect network configured to convey data between the cores and the lower-level cache. The controllers may share access to an interconnect egress port coupled to the interconnect network, and may generate multiple concurrent requests to convey data via the shared port, where each of the requests is destined for a corresponding core, and where a datapath width of the port is less than a combined width of the multiple requests. The given tag unit may arbitrate among the controllers for access to the shared port, such that the requests are transmitted to corresponding cores serially rather than concurrently. | 07-28-2011 |
20120239883 | RESOURCE SHARING TO REDUCE IMPLEMENTATION COSTS IN A MULTICORE PROCESSOR - A processor may include several processor cores, each including a respective higher-level cache; a lower-level cache including several tag units each including several controllers, where each controller corresponds to a respective cache bank configured to store data, and where the controllers are concurrently operable to access their respective cache banks; and an interconnect network configured to convey data between the cores and the lower-level cache. The controllers in a given tag unit may share access to a resource that may include one or more of an interconnect egress port coupled to the interconnect network, an interconnect ingress port coupled to the interconnect network, a test controller, or a data storage structure. | 09-20-2012 |